Advanced clinical trials of dendritic cell vaccines in ovarian cancer

J Investig Med. 2020 Oct;68(7):1223-1227. doi: 10.1136/jim-2020-001355. Epub 2020 Jul 27.


Epithelial ovarian cancer (EOC) is the most common and leading cause of death for gynecologic cancer in the western world. Current standard treatments with limited selection of chemotherapies cannot meet patients' urgent needs. Immunotherapies have recently demonstrated clinical benefits in a variety of solid tumors and may offer a promising frontier for treating EOC. Dendritic cells (DCs) are key coordinators of the innate and adaptive immune system in induction of antitumor immunity. DC-based vaccinations showed clinical benefits and encouraging safety profiles in a few phase II clinical trials for patients with EOC and currently are in a phase III double-blind, randomized, placebo-controlled clinical trial. In this review, we have searched Pubmed and Clinicaltrials. gov databases for past and current phase II or phase III clinical trials with focus on EOC and DC vaccines. Outcomes and implications of the completed and ongoing trials are discussed.

Keywords: immunotherapy, adoptive; ovarian neoplasms; vaccination.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antigens, Neoplasm / metabolism
  • Cancer Vaccines / immunology*
  • Clinical Trials as Topic*
  • Dendritic Cells / immunology*
  • Female
  • Humans
  • Ovarian Neoplasms / immunology*


  • Antigens, Neoplasm
  • Cancer Vaccines